Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Sanofi ( (SNY) ).
On November 3, 2025, Sanofi announced the issuance of $3 billion in notes, including floating and fixed rate notes due in 2027, 2028, and 2032. This strategic financial move is expected to enhance Sanofi’s capital structure and support its long-term growth objectives, potentially impacting its market position and providing liquidity for future investments.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by strong earnings call performance and attractive valuation. Financial stability and solid profitability support the score, despite some challenges in cash flow and revenue growth. Technical analysis indicates a stable market position, contributing to a positive outlook.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a global healthcare company based in Paris, France, primarily focused on pharmaceuticals and vaccines. It operates in various therapeutic areas, including diabetes, cardiovascular diseases, and oncology, and is a significant player in the global healthcare market.
Average Trading Volume: 3,127,707
Technical Sentiment Signal: Strong Buy
Current Market Cap: $123.1B
For detailed information about SNY stock, go to TipRanks’ Stock Analysis page.